ABSTRACT
Objective To establish a druggability evaluation method for new targets of anti-tumor drugs by analyzing the mutation genes of common tumors in the digestive system. Methods We collected the mutant gene data of the five common tumors of the digestive system (esophageal cancer, gastric cancer, colorectal cancer, liver cancer and pancreatic cancer) in the Integrative Onco Genomics database, and screened out the genes with higher mutation rates in each tumor. We evaluated the druggability of these genes or their encoded proteins, and discovered the potential targets for the new anti-tumor drugs. Results A total of five tumors, 35 cohorts and 5445 tumor samples were collected in this study. The top 10 mutation genes were selected for further analysis. The canSAR database was used to analyze the druggability of unpublished mutant genes or their encoded proteins, and a total of 17 potential therapeutic drug targets were screened out. Conclusion A method for evaluating druggability of targets based on mutant genes or their encoded protein is established in this study. The application of this method can provide a reference for discovering new anti-tumor therapeutic target, saving the cost and time of target screening in new drug development.
ABSTRACT
Objective To investigate the clinical effect of edaravone on free radical damage after acute stroke. Methods The 60 patients with acute stroke were randomly divided into therapy group and control group. Both the groups were treated with routine approaches of dehydration, intracranial pressure reducing and blood pressure control. The treatment with balanced saline 250 ml plus edaravone 30 mg, intravenously infusion twice a day, was adopted in therapy group, while the control group received balanced saline 250 ml only, the treatment lasted for 14 days. Before and 14 days after treatment, the neurologic impairment analysis, activity of daily living scale (ADL) and serum superoxide dismutase (SOD) were checked. Results Compared with control group, after 14 dtreatment, the improvements in neurologic impairment analysis (7.5±5.4 vs. 15.9±7.9, P＜0.05),ADL (58.32±11.57 vs. 43.73± 12.48, P＜0.05) and SOD[(157.25±21.81)mmol/L vs. (127.08 ± 13. 14)mmol/L, P＜0. 05] occurred in therapy group. Conclusions Edaravone could increase the ability of cleaning free radicals and promoting function of nerves recovery.